CU24163B1 - Composición farmacéutica oftalmológica tópica que contiene regorafenib - Google Patents

Composición farmacéutica oftalmológica tópica que contiene regorafenib

Info

Publication number
CU24163B1
CU24163B1 CU20130168A CU20130168A CU24163B1 CU 24163 B1 CU24163 B1 CU 24163B1 CU 20130168 A CU20130168 A CU 20130168A CU 20130168 A CU20130168 A CU 20130168A CU 24163 B1 CU24163 B1 CU 24163B1
Authority
CU
Cuba
Prior art keywords
typical
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
containing regorafenib
Prior art date
Application number
CU20130168A
Other languages
English (en)
Other versions
CU20130168A7 (es
Inventor
Michael Böttger
Degenfeld Georges Von
Julia Freundlieb
Claudia Hirth-Dietrich
Joerg Keldenich
Jürgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Riedl
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24163(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20130168A7 publication Critical patent/CU20130168A7/es
Publication of CU24163B1 publication Critical patent/CU24163B1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CU20130168A 2011-06-28 2012-06-26 Composición farmacéutica oftalmológica tópica que contiene regorafenib CU24163B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14
PCT/EP2012/062365 WO2013000917A1 (en) 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib

Publications (2)

Publication Number Publication Date
CU20130168A7 CU20130168A7 (es) 2014-04-24
CU24163B1 true CU24163B1 (es) 2016-03-31

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130168A CU24163B1 (es) 2011-06-28 2012-06-26 Composición farmacéutica oftalmológica tópica que contiene regorafenib

Country Status (26)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
PH (1) PH12013502691A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034797A1 (en) 2004-09-29 2006-04-06 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
ES2971096T3 (es) * 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
CA2611720A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
PL1968594T3 (pl) 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
JP2009519267A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および/または耳疾患を処置するためのジアリールウレア
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2156833B1 (en) * 2007-05-11 2011-11-30 Santen Pharmaceutical Co., Ltd Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN102573477A (zh) 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法

Also Published As

Publication number Publication date
WO2013000917A1 (en) 2013-01-03
PE20141031A1 (es) 2014-08-21
JP2014518233A (ja) 2014-07-28
AR086800A1 (es) 2014-01-22
CR20130693A (es) 2016-05-02
UY34166A (es) 2013-01-31
CN103889399A (zh) 2014-06-25
HK1197176A1 (en) 2015-01-09
NZ619229A (en) 2016-04-29
DOP2013000314A (es) 2014-04-15
AP2013007335A0 (en) 2013-12-31
AU2012277905A1 (en) 2014-01-16
MX2013015287A (es) 2014-03-31
TN2013000533A1 (en) 2015-03-30
BR112013033831A2 (pt) 2017-02-14
EP2726059A1 (en) 2014-05-07
GT201300322A (es) 2014-11-13
ECSP13013106A (es) 2014-01-31
CU20130168A7 (es) 2014-04-24
PH12013502691A1 (en) 2017-08-23
CA2840329A1 (en) 2013-01-03
CL2013003700A1 (es) 2014-07-18
AU2012277905A8 (en) 2014-01-30
JP5998213B2 (ja) 2016-09-28
KR20140048218A (ko) 2014-04-23
EA201400064A1 (ru) 2014-05-30
US20140296301A1 (en) 2014-10-02
CO6920289A2 (es) 2014-04-10
ZA201400646B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
DK2694038T3 (da) Farmaceutisk sammensætning
SMT201700008B (it) Composizione farmaceutica
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK3246018T3 (da) Farmaceutisk sammensætning
EP2758052A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
EE201300005A (et) Ravimkoostis
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
DK2897594T3 (da) Farmaceutisk sammensætning
DK2815752T3 (da) Oral farmaceutisk sammensætning
EP2769718A4 (en) MEDICAL COMPOSITION
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
EP2815753A4 (en) ORAL PHARMACEUTICAL COMPOSITION
SMT201500005B (it) Composizione framaceutica inalabile
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
BR112015002646A2 (pt) composto e composição farmacêutica
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
HRP20160928T1 (hr) Farmaceutske kompozicije koje sadrže anakinra bez citrata
BR112012029887A2 (pt) composição farmacêutica
PL395069A1 (pl) Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
PL2638894T3 (pl) Kompozycja farmaceutyczna z fosfolipidem
BR112014016122A2 (pt) composto, e, composição farmacêutica

Legal Events

Date Code Title Description
FG Grant of patent